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Giant axonopathy (gaxp), an autosomal recessivemouse mutation, exhibits ataxia of the hind legs with a slight side-to-side wobble while walking.
Within the genomic region of the gaxp locus, a total of 94 transcripts were identified; the annotation of these genes using OMIM and PubMed yielded
three potential candidate genes. By cDNA microarray analysis, 54 genes located on or near the gaxp locus were found to exhibit differential
expression between gaxp and littermate controls. Based on microarray data and the known function of genes identified, Slc12a6 was selected as the
primary candidate gene and analyzed using the Reveal technology of SpectruMedix. A 17-base deletion was detected fromwithin exon 4 of Slc12a6.
Reverse transcriptase polymerase chain reaction validated the difference in Slc12a6 expression in different types of mice at the mRNA level,
revealing a marked reduction in gaxp mice. Western blot analysis indicated that the protein product of Slc12a6, the K+-Cl- cotransporter Kcc3, was
not detectable in gaxp mice. The causative role of the exon 4 mutation within Slc12a6 in the gaxp phenotype was further confirmed by screening
multiple inbred strains and by excluding the mutation of nearby genes within the gaxp locus.
© 2008 Elsevier Inc. All rights reserved.Keywords: Genome; Giant axonopathy; High-throughput screening; Microarray; Mouse; MutationGiant axonopathy (gaxp) is a new autosomal recessive mutation
that arose spontaneously in a mutant strain on the C3H/HeDiSnJ
background in the Mouse Mutant Resource at The Jackson
Laboratory (TJL) (http://www.jax.org/mmr/MMR_Mutant_gaxp.
html). Homozygous mutants exhibit ataxia of their hind legs,
characteristically lifting their hind legs too high and wobbling side-
to-side as they walk. When mutants are pulled backward by their
tails, they curl their hind legs toward their bodies, whereas normal
mice actively move their legs to resist being pulled backward. The
swollen axons observed in gaxp/gaxp mice are a unique form of⁎ Corresponding author. Department of Orthopaedic Surgery (Campbell
Clinic), University of Tennessee Health Science Center, Memphis, TN 38163,
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doi:10.1016/j.ygeno.2007.12.010axonal dystrophy. Whereas the normal dystrophic axons are
densely eosinophilic and are composed of densely packed
organelles and filamentous material, the axons in these mutants
contain only lightly packed organelles, suggesting that the swelling
is due in part to an increased uptake of water. The inherited diseases
of children characterized by dystrophic axons include infantile
neuroaxonal dystrophy (INAD) and giant axonal neuropathy
(GAN). These are characterized histopathologically by accumula-
tion of the dense form of dystrophic axons. INAD (also known as
Seitelberger disease) is a rare autosomal recessive hereditary
neurodegenerative disease of humans [1–4]. GAN is an autosomal
recessive neurologic disorder clinically characterized by a severe
polyneuropathy, central nervous system abnormalities, and char-
acteristic tightly curled hair; mutations in the gigaxonin gene have
recently been identified as the underlying genetic defect [5–8].
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locus; it is likely that the gaxp phenotype is caused by a new
mutation in a gene that has not been functionally related to the
dystrophic axons. Identifying the mutated gene in the gaxp locus is
essential to understanding this mouse model and to investigating
the molecular cause(s) of dystrophic axons.
According to TJLWeb page information, the gaxpmutation is
on chromosome (Chr) 2. The most likely gene order places the
mutation between D2Mit128 and D2Mit102 in 174 meioses
tested. The recombination estimates with standard errors and best
gene order are centromere–D2Mit386–3.04±1.3–D2Mit249–
1.18±0.83–D2Mit128–1.75±1.00–gaxp–D2Mit102–1.17±
0.82–[D2Mit484, D2Mit17]–18.82±4.0–D2Mit51.
The completion and annotation of themurine genome sequence
has yielded a powerful tool for positional cloning [9–11]. First, all
of the coding sequences within a given chromosomal region of
interest can be identified. Second, information on the introns and
5′ and 3′ regions of the sequences is generally available, making it
possible for the gene to be analyzed thoroughly throughout the
coding region and the regulatory region. Third, the genomic
sequence of a given region facilitates the analysis of nucleotide
organization, gene ordering, gene expression patterns, and
chromosomal structure. The availability of this information has
coincided with the development of high-throughput technologies
for both mutation analysis and gene expression profiling. All of
these developments will have considerable effect on the search for
candidate genes in positional cloning.
Here we report the identification of the mutated gene in the
gaxp model by using an integrated genomic strategy, encom-
passing high-throughput screening of genomic elements [10,11],
gene expression profiles, and gene function searching.
Results
Phenotype of gaxp mice
All gaxp/gaxp mice housed at the University of Tennessee
Health Science Center exhibited ataxia of hind legs at the age ofFig. 1. Phenotype of normal and gaxp littermates. (A) The hind legs of a gaxp/gaxpm
(B) A gaxp/gaxp mouse failed to resist positively when it was pulled backward by its14 days and a slight side-to-side wobble while walking. Two
other tests distinguished gaxp/gaxp mice from unaffected
littermates. First, as the mice walked, we exerted backward
traction on their tails; the gaxp/gaxp mice were not able to use
their hind legs actively to resist. Second, we found that the hind
legs of gaxp/gaxpmice clamped together toward the body when
held downward by the tail (Fig. 1). No differences were noted
between the gaxp/+ and the +/+ mice.
Target region of the mutation in the gaxp locus
To select candidate genes, we first identified all possible genes
within the gaxp region. Previous genetic analysis showed that the
gaxpmutation is located onmouseChr 2, flanked by themolecular
markers D2Mit128 and D2Mit102 (http://www.jax.org/mmr/
gaxp.html). According to the Ensembl database, D2Mit128 is
located between 106121793 and 106122031 bp, whereas
D2Mit102 is located between 113984330 and 113984492 bp
(Fig. 2A). Genomic sequences within this region are complete in
the Ensembl database. There are a total of 94 transcripts in this
region, with 82 known genes and 56 that correspond to novel
genes or pseudogenes.
Informational search of gene functions within the targeted
region
To prioritize the transcripts, we conducted a bioinformatics
search of the function of every gene within the gaxp region to see
whether any genes seemed functionally relevant to the gaxp
phenotype. For each gene, we searched its function in OMIM
(for keywords anywhere in the gene description) and PubMed
(words in the title or abstract) with the terms “ataxia,” “axons,”
“wobble,” “eosinophilic,” and “neuropathy.” From those genes,
we identified three candidates: brain-derived neurotrophic factor
(Bdnf), ryanodine receptor 3 (Ryr3), and solute carrier family 12,
member 6 (Slc12a6) (Table 1) (Refs. [12–22]).
At the TJL Web site, two genes, brain-derived neurotrophic
factor precursor and voltage-gated potassium channel protein,ouse came together and its body curled when it was held upside down by the tail.
tail. In both (A) and (B), the normal mouse is the littermate of the gaxp mouse.
Fig. 2. Schematic of the mutation identification in gaxp/gaxpmice. (A) A genetic map of the gaxp locus showing the relative locations of microsatellite markers and the total
number of candidate transcripts within the gaxp locus. (B) PCR product analyses using the SpectruMedix system. The PCR products from different mice were compared to
check the possible sequence difference between normal C3H/HeDiSnJ mice (+/+), homozygous gaxp/gaxp mice, and heterozygous +/gaxp mice. (C) Expression level of
Slc12a6 in gaxp and control mice. Amplification of Slc12a6 transcript from total RNA extracted from cerebella, cerebra, muscle, liver, and spleen of +/+ and gaxp/gaxpmice.
Table 1
Candidate genes based on bioinformatics literature search
Search term Gene
symbol
Gene name OMIM PubMed
Ataxia Bdnf Brain-derived
neurotrophic factor
0 7 (Refs. [12–15])
Axons Bdnf Brain-derived
neurotrophic factor
0 270 (Refs. [12–15])
Ryr3 Ryanodine receptor 3 0 1 (Ref. [16])
Eosinophilic Bdnf Brain-derived
neurotrophic factor
0 1 (Refs. [16,17])
Neuropathy Slc12a6 Solute carrier family 12,
member 6
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candidate genes. However, our literature analysis did not iden-
tify Kcna4 as a likely candidate.
Gene expression levels of genes within the gaxp region
Abnormal gene expression has previously been used as a
revealing fingerprint of disease genes [10,11]. Using Affymetrix
microarray chips, we analyzed the gene expression level of
each of three normal and three gaxp/gaxp mice. Of 2642 probes
on mouse Chr 2, 768 are located between 100 and 130 Mb;
within this subset, the expression levels of 22 probes were
down-regulated and 32 were up-regulated. The Slc12a6 gene
is among those genes that are down-regulated in gaxp/gaxp
mice, as detected by two probes on the chip; this result tagged
Slc12a6 as a promising candidate for the gaxp gene. In con-
trast, the expression of Bdnf and Ryr3 appeared to be eitherunaffected or slightly up-regulated (Table 2), whereas there was
no difference in Kcna4 expression between gaxp mice and
controls.
Table 2
Comparison of expression of candidate genes in gaxp and in normal mice
Gene gaxp signal WT signal gaxp/WT signal log ratio Interpretationa
Bdnf 415.6 566 −0.0 NC
639.7 445.2 0.4 I
Ryr3 979.4 856.5 0.4 NC
339.6 183.2 0.7 I
Slc12a6 501.6 1200.4 −1.1 D
51.8 234.4 −1.9 D
Kcna4 274.3 226.1 0.6 NC
230.9 168.5 0.5 NC
aNC, no change; I, increased expression level; D, decreased expression level.
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Based on the results of our bioinformatics and microarray
analyses, Slc12a6 was the first priority in our search for the
mutated gene from this model, with Bdnf and Ryr3 as secondary
candidates.
We first conducted polymerase chain reaction (PCR) ampl-
fication of each exon of Slc12a6, a large gene located in theFig. 3. Sequence changes of Slc12a6 gene in gaxp mice. (A) There are two sequenci
the normal littermate as control; the right presents cDNA sequences of Slc12a6 from
deleted from gaxp mice. Notice that a T also was inserted when the 17 bases were de
(brown). The mutation leads to a frameshift change of 12 amino acids and a subseque
levels. (Top) The expression of protein product, Kcc3, in kidney and cerebra in twogenomic sequence between 112,067,658 and 112,163,995 on
mouse Chr 2. Slc12a6 encompasses 25 exons, with a 2081-base
untranslated 3′ end. Three kinds of PCR products were screened
by Reveal (SpectruMedix): DNA fragments from gaxp, normal
littermates, and a mixture of gaxp and normal mice. Among
these amplificons, using primers flanking exon 4 from Slc12a6
we found that one fragment differed between gaxp and controls
(Fig. 2B).
Given this apparent difference in the Slc12a6 gene between
gaxp and control mice, we further analyzed the expression level
of Slc12a6 by reverse transcriptase polymerase chain reaction
(RT-PCR). A pair of primers that flank exons 3–5 was used to
amplify cDNA from several tissues. As shown in Fig. 2C, the
expression level of Slc12a6 was lower in gaxp mice than in
controls.
To determine which nucleotide(s) was different between
gaxp/gaxp mice and their littermate controls, we sequenced
genomic DNA fragments from gaxp/gaxp and control mice. The
data revealed a 17-base deletion within exon 4 in DNA from
gaxp/gaxp mice (Fig. 3A). To confirm this mutation at theng panels. The left presents genomic sequences of Slc12a6 from gaxp mice and
gaxp mice and the normal littermate. In both cases, 17 base nucleotides are the
leted. (B) Derived amino acid sequences of normal (black) and mutant Slc12a6
nt stop codon. (C) The Slc12a6 mutation has dramatic effects at its translational
gaxp mice and two wild-type controls. (Bottom) The expression of β-actin.
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gaxp, gaxp/+, and +/+ mice using primers that covered the
mRNA sequence from exon 3 to exon 5 of the Slc12a6 gene. The
resultant RT-PCR products were sequenced using the Spectru-
Medix system, and the same deletion in gaxp/gaxp was found
(Fig. 3A, right).
Analysis of Kcc3, the protein product of Slc12a6, in gaxp mice
To detect the effect of the exon 4 deletion at the protein level,
Western blot analysis was conducted using tissues from kidney
and brain to detect the protein encoded by Slc12a6, the Kcc3
K+-Cl- cotransporter. We used a well-characterized antibody
specific for a peptide within exon 3 of Slc12a6 [24]; should a
Kcc3 protein product be generated in these mice, it should be
detected by this antibody, given that the gaxp deletion is in exon
4 of Slc12a6. Whereas the Kcc3 protein was detected in both
tissues in normal littermates, it was not detected in gaxp mice
(Fig. 3C). The data suggested that the frameshift change of 12
amino acids may lead to nonsense-mediated decay (NMD) [11]
of the gaxp Kcc3 protein.
Confirmation of mutation
We conducted two experiments to ensure further the link
between the mutation and the disease. First, we examined se-Fig. 4. Size differences of PCR products from gaxpmice and 12 mouse inbred strains
Str/ort, MA/HyJ, A/J, AKR/J, PL/J, S/J, RIIIS/J, and A/wySnJ. (Right two) Mixture
represents relative sizes of the PCR products. The y axis represents relative strengthquence polymorphism in exon 4 of Slc12a6 from nine additional
inbred strains. As shown in Fig. 4, while the mixture of DNA
fragments from those 12 strains appeared as a single signal, the
mixture with gaxp appeared as two signals, indicating the
difference between gaxp/gaxp and the other strains. Second, we
screened 121 other candidate genes within the gaxp region by
using our SpectruMedix mutation detection system [10]; we
detected no other potential mutations, indicating that Slc12a6 is
the only gene with a coding sequence mutation in the gaxp locus.
Discussion
Using a combination of functional bioinformatics analysis
and microarray screening of a large genome region (see
Methods), we identified the mutant gene responsible for the
gaxp phenotype. The initial mapping at TJL was conducted
with only 21 mutant mice. Linkage of gaxpwas first detected on
Chr 2 with D2Mit128 and D2Mit102 by using the pooled
sample. DNA samples were then typed for the individual 87
animals with these two and other markers and Chr 2 markers
(http://www.jax.org/mmr/gaxp.html). The gaxp locus should be
further mapped using classical candidate positional cloning,
because there is a multitude of candidate genes in this region of
Chr 2. However, with the availability of mouse genome infor-
mation and the rapidly evolving understanding of gene function
[9–11], the likelihood of detecting candidate genes based on a. (Left two) PCR products from 12 mouse inbred strains, C3H, DBA, B6, Balb/c,
of PCR products from gaxp/gaxp mice in 12 mouse inbred strains. The x axis
s of signal or the amounts of the PCR products.
412 Y. Jiao et al. / Genomics 91 (2008) 407–414rough genetic map is considerably increased.With our success at
finding this mutation and others [10,11], we feel that in the near
future we will no longer need fine mapping to identify mutated
genes in many mouse strains with Mendelian phenotypes.
Several lines of evidence indicate that a 17-nucleotide
deletion of Slc12a6 is causally associated with the gaxp
phenotype. First, Slc12a6 is located within the genetic region
of the gaxp locus. Second, the Slc12a6 mutation was the only
defect detected in gaxp mice among candidate genes (Fig. 2)
within the gaxp locus. There were thus no other differences
between gaxp/gaxp mice and their parental strains, so that the
possibility of coding sequence mutations in other genes in this
interval was ruled out. Third, cDNA sequence results agreed
with the genomic DNA data. Fourth, gene network and real-
time PCR indicated that Slc12a6 is the key that influences the
differential expression of genes in gaxp mice. Finally, the 17-
nucleotide deletion in Slc12a6 is predicted to delete some 6
amino acids from the Kcc3 protein, leading to a stop codon
and removing the entire 12-transmembrane hydrophobic core
through which K+ and Cl- are transported. No Kcc3 protein,
truncated or full length, was detected using an antibody directed
against an epitope from within exon 3 of Slc12a6. These
experiments strongly indicate that loss of function in Slc12a6 is
the cause of the gaxp phenotype.
Prior published reports have identified a spectrum of disease
phenotypes associated with loss of Kcc3 function. The first
study indicated that single-nucleotide mutations in human
SLC12A6 cause a peripheral neuropathy associated with
agenesis of the corpus callosum (ACCPN), a severe sensor-
imotor neuropathy associated with mental retardation, dys-
morphic features, and complete or partial agenesis of the corpus
callosum [20]. In the same report, mice with a targeted deletion
in exon 3 of Slc12a6 had a locomotor deficit, peripheral neuro-
pathy, and a sensorimotor gating deficit. A second knockout was
independently generated by fusing the first conserved exon in-
frame to β-galactosidase [23]; these mice suffered from deaf-
ness, neurodegeneration, and reduced seizure threshold. Nota-
bly, central neurodegeneration was not identified in the mice
with a targeted deletion of exon 3, despite careful histopathology
[20]. Most recently, Uyanik et al. [18] showed that not only
truncating but also missense mutations of the KCC3 gene are
associated with ACCPN, with a spectrum of mental retardation
and progressive sensorimotor neuropathy, depending on the
specific disease-associated mutation in SLC12A6. As Slc12a6
contains 25 exons and encodes several different Kcc3 isoforms,
varying in the composition of the cytoplasmic N-terminal
domain [21,24–27], it is possible that it has multiple functions
in a variety of pathways. Notably, however, swelling-activated
K+-Cl- cotransport mediated by KCC3 appears to play a critical
role in neuronal volume regulation [23], and a recent report has
implicated axonal and periaxonal swelling in the peripheral
neuropathy associated with Kcc3 deficiency [28]. The differ-
ences in the phenotypes of gaxp mice, the two published
knockout mice, and humans with truncating versus nonsense
mutations in SLC12A6 are provocative and suggest that several
other factors modulate the effect of KCC3 deficiency in both the
central and the peripheral nervous systems.The protein product, Kcc3, was undetectable in gaxp mice,
suggestive of NMD. NMD, first documented by Losson and
Lacroute over 20 years ago [29], is a proofreading mechanism
that enables eukaryotic cells to detect and degrade mRNAs that
contain premature termination codons (PTCs). About one-third
of inherited genetic disorders and many forms of cancer are
caused by frameshift or nonsense mutations, which result in the
generation of PTCs [30,31]. Although mRNA containing a PTC
may initially be translated into a truncated protein, cells can
initiate the NMD mechanism to recognize and degrade the
mutant transcripts if the truncated protein is deleterious, as we
previously reported in a waddles mouse model [11].
Slc12a6 was not in the list of candidate genes for allelism
tests at TJL. According to the information on TJL Web page
(http://www.jax.org/mmr/lbab.html), allelisms tested were anor-
exia, with a ratio of disease/total at 0/50 progeny born, and
hotfoot, with a ratio of 0/17 progeny born. In addition, Kcna4
and Bdnf, but not Slc12a6, were listed as candidate genes. In
aggregate, we feel our study suggests that it is extremely im-
portant to conduct a comprehensive expression and bioinfor-
matics analysis for any known disease locus for which the
mutated gene has not yet been discovered.
Methods
Strategy of mutation analysis
Fig. 5 shows the strategy we used to identify mutated genes from mouse
disease models. The high-throughput technology for screening a large number of
genes by using the SpectruMedix system identified three other mutations. In the
current study, bioinformatics searching and gene expression profiles made the
screening simpler and more efficient.
Mice
A heterozygous (gaxp/+) breeding pair of mice was purchased from TJL, and
a breeding colonywas established at the research animal facility of the University
of Tennessee Health Science Center. Homozygous mutation gaxp/gaxp, het-
erozygous gaxp/+, and homozygous normal +/+ mice produced from the
heterozygous parents were used in this study for mutation identification and
protein analysis. Experimental animal procedures and mouse husbandry were
performed in accordance with the National Institutes of Health's Guide for the
Care and Use of Laboratory Animals and approved by the UTHSC Institutional
Animal Care and Use Committee.
Mutation screening
Based on the Ensembl and National Center for Biotechnology Information
databases as of March 7, 2007, primer pairs flanking the exons of known and
predicted genes (including expressed sequence tags) within the gaxp locus were
designed using Primer3 software (http://www-genome.wi.mit.edu/cgi-bin/
primer/primer3_www.cgi). Primers were located approximately 100 bp 5′ or
3′ to each exon and, in general, produced 300- to 400-bp amplicons. For large
exons that required multiple pairs of primers, primers were designed to allow
neighboring DNA fragments to overlap each other by at least 50 bp. Primer pairs
were synthesized by Illumina (www.illumina.com). PCR amplification of
gDNAwas performed in a 96-well plate format and consisted of 30–35 cycles at
three temperatures: strand denaturation at 96 °C for 30 s, primer annealing at
54–60 °C for 60 s, and primer extension at 72 °C for 120 s.
ATGCE device made by SpectruMedix was used to analyze amplicons from
+/+, +/gaxp, and gaxp/gaxp mice. The SpectruMedix system includes a high-
throughput capillary electrophoresis instrument capable of analyzing 96 sam-
ples every 140 min. Heteroduplex analysis was subsequently performed using
Fig. 5. Schematic illustration of strategy of mutation identification in our laboratory. In Step 1, transcripts are identified based on the Ensembl database, http://www.
ensembl.org. In Step 2, functional information of candidate genes is obtained from the Online Mendelian Inheritance in Man (OMIM) Web site (http://www.ncbi.nlm.
nih.gov/entrez/query.fcgi?db=OMIM) and PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed), while the gene expression profile comes from the
whole-genome microarray analysis. In Steps 3, 4, and 5, screening of possible mutations is done with the SpectruMedix high-throughput system. In case a mutation is
identified, any of the steps goes directly to Step 6. In Step 7, multiple sequence comparison can be done through multiple mouse strains or a large population from a
segregated F2 or recombinant inbred line. In Step 8, the effect of a mutation can be predicted through multiple analyses such as sequence analysis, Western blot, and
histobiochemistry analysis.
413Y. Jiao et al. / Genomics 91 (2008) 407–414SpectruMedix software. Amplicons from gaxp mice were sequenced if they
differed from normal ones. Heteroduplex analysis was done with our previously
reported protocol [10,11].
Genotyping
A pair of primers flanking exon 4 of Slc12a6 (forward primer,
CCCTCAGCTCCACACAGTCT; reverse primer, TTCTTCACATGGATG-
GATGC) was used to genotype +/+, gaxp/+, and gaxp/gaxp mice. The PCR
products from heterozygous and homozygous mice were mixed with those from
normal mice. The individual and mixed PCR products were then run on TGCE to
detect possible sequence variations. PCR amplification was performed in a total
volume of 25 µl at a final concentration of 1.5 mMMgCl2 and 0.2 mmol/L each
dNTP, 0.2 µmol/L oligonucleotide primer, 100 ng template DNA, and 0.7 units
Taq polymerase (Fisher Scientific, Pittsburgh, PA, USA) for 35 cycles of 94 °C
for 1 min, 50–55 °C for 1 min, and 72 °C for 2 min.
RT-PCR amplification of Slc12a6
A One-Step RT-PCR kit (Invitrogen, Carlsbad, CA, USA) was used to detect
the expression of mutated Slc12a6 at the mRNA level. Reactions were performed
in a total volume of 50 µl with 8 ng/µl total RNA, and 0.2 μM forward
(ATTCAGGATCCCCAAGAACC) and reverse (AAGACGCAGGAAGAG-
GATCA) primers were used to amplify exons 2 to 3 of Slc12sa6. First, cDNA
synthesis and predenaturation were performed in single cycles at 50 °C for 40 min
and 94 °C for 2 min. Next, PCR amplification was performed for 35 cycles: 94 °C
for 30 s, 54–58 °C for 36 s, and 72 °C for 2 min.Gapdh was used as control with
the same amplification protocol and cycle number.
DNA sequencing
DNA sequencing was conducted to verify the mutation in the gDNA and
cDNAof Slc12a6 from different species of mice. PCR products from both gDNA
and cDNA were purified using an AMPure PCR purification kit (Agencourt,
Beverly,MA,USA), and the resultant productswere sequenced using the BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA,
USA). A total volume of 5 μl sequencing reactions including 2 µl Big Dye (plus
Half-BD), 10 to 23 ng of purified DNA template, and 1 to 3 pmol of either
forward or reverse universal sequencing primers was incubated for 37 cycles
at 96 °C for 180 s, 50 °C for 30 s, and 60 °C for 180 s. Unreacted primers were
removed by ethanol–acetate precipitation (3.75% 3 M NaOAc, 87.5% non-
denatured 100% EtOH, and 8.75% dH2O, pH 4.6). The labeled products weredissolved in 0.02 mM EDTA in HiDi formamide prior to being loaded
electrophoretically onto the SpectruMedix 96 capillary sequencing system. The
same primers in the amplification of DNA fragments from either genomic DNA
ormRNAwere also used in the sequencing. Sequencingwas conducted two times
to verify the results for either gDNA or cDNA.
Western blot analysis
Cerebra and kidney from two pairs of wild-type C3H/HensJ and gaxp/gaxp
mice were dissected and homogenized in sucrose buffer (0.32 M sucrose, 5 mM
Tris–HCl, pH 7.5, 2 mM EDTA) and ground with a Dellco pestle. Protein was
obtained by centrifugation at 25,000 ×g, 60 min, and a total of 40 µg/well was
loaded on a 6–10% gradient SDS–PAGE gel. Proteins were then electrophor-
etically transferred to PVDF membranes (Bio-Rad, Hercules, CA, USA). The
antibody to Kcc3 was specific for a peptide epitope from within exon 3 of
Slc12a6; membranes were probed with affinity-purified Kcc3 antibody at a
dilution of 1:1000. Proteins were detected using ECL Plus detection system
(Amersham, Arlington Heights, IL, USA) [27].
Microarray analysis
Individual total RNA samples from wild-type and gaxp mice (three each)
were pooled separately into two groups for a pilot microarray assay. Five
micrograms of total RNAwas used for each chip. Microarray hybridization and
data generation were performed according to Affymetrix guidelines using
GeneChip Mouse Genome 430 2.0 arrays, cDNA and cRNA synthesis kits, and
GCOS 1.4 software (www.affymetrix.com). Raw data were normalized using
the MAS5 algorithm, and comparative analysis was carried out between wild-
type and mutant datasets using GCOS 1.4. Functional clustering was performed
with DAVID tools (http://david.abcc.ncifcrf.gov).Acknowledgments
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